AllergyTalk
AllergyTalk delivers the latest insights and evidence shaping allergy and immunology. In each bimonthly episode, leading experts break down the most impactful research and real-world takeaways from AllergyWatch®, a bimonthly publication summarizing key findings from 20 major journals in allergy and asthma.
AllergyTalk delivers the latest insights and evidence shaping allergy and immunology. In each bimonthly episode, leading experts break down the most impactful research and real-world takeaways from AllergyWatch®, a bimonthly publication summarizing key findings from 20 major journals in allergy and asthma.
Episodes
Thursday Apr 09, 2020
Episode 10: OIT Safety, OR Anaphylaxis, and IT for Cats
Thursday Apr 09, 2020
Thursday Apr 09, 2020
For this episode, we will be reviewing three articles from the Nov-Dec 2019 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. To subscribe to Allergy Watch, head over to https://college.acaai.org/publications/allergywatch
We’re pleased to introduce CME credit for Allergy Watch episodes of AllergyTalk! For details, head on over to the AllergyTalk webpage at https://college.acaai.org/allergytalk
Article Links:
Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety.
Paired acute-baseline serum tryptase levels in perioperative anaphylaxis: An observational study.
Immunization of cats to induce neutralizing antibodies against Fel d 1, the major feline allergen in human subjects.
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Drs. Lee and Kalangara have nothing to disclose.
Dr. Fineman: Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.
Thursday Apr 09, 2020
Episode 9: Asthma Epidemiology, Diet, and More on MART Therapy
Thursday Apr 09, 2020
Thursday Apr 09, 2020
For this episode, we will be reviewing three articles about asthma from the Nov-Dec 2019 issue of Allergy Watch, a bimonthly publication which provides research summaries to College members from the major journals in allergy and immunology. To subscribe to Allergy Watch, head over to https://college.acaai.org/publications/allergywatch
We’re pleased to introduce CME credit for Allergy Watch episodes of AllergyTalk! For details, head on over to the AllergyTalk webpage at https://college.acaai.org/allergytalk
Article Links:
Racial disparities in asthma-related health care use in the National Heart, Lung, and Blood Institute's Severe Asthma Research Program.
Omega-3 and Omega-6 Intake Modifies Asthma Severity and Response to Indoor Air Pollution in Children.
Controlled Trial of Budesonide-Formoterol as Needed for Mild Asthma.
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Drs. Lee and Kalangara have nothing to disclose.
Dr. Fineman: Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.
Friday Mar 27, 2020
Episode 8 part 2 - How the College Supports Allergists - Practice Management
Friday Mar 27, 2020
Friday Mar 27, 2020
Welcome to Episode 8, part 2 of Allergy Talk! I sat down with my co-host Stan Fineman, MD, MBA, ACAAI to review the practice management resources from the ACAAI!
If you have a topic you’d like to cover in a future podcast, let us know at allergytalk@acaai.org.
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.
Dr. Lee has no relevant disclosures.
Friday Mar 13, 2020
Friday Mar 13, 2020
Welcome to Episode 8 of Allergy Talk, a roundup of the latest in the field of Allergy and Immunology by the American College of Allergy, Asthma, and Immunology!
At the 2019 ACAAI Annual Meeting in Houston, Texas we interviewed the leaders of the College on how the ACAAI helps its members and what to expect for 2020! If you have a topic you’d like to cover in a future podcast, let us know at allergytalk@acaai.org.
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Dr. Mahr:
Research / Consultant / Advisory Board / Speaker / Honorarium:
Aimmune, ALK, AZ, Boeringer-Ingelheim, Kaleo, GSK, Optinose, Sanofi-Genzyme - Regeneron
Dr. Meadows:
Speaker: Regeneron, Pfizer, AZ, GSK, Optinose
Consultant: Aimmune
Dr. Lee:
No relevant disclosures
Monday Feb 10, 2020
Episode 7 - Part II: An Interview with Dr. Brian Vickery
Monday Feb 10, 2020
Monday Feb 10, 2020
We are excited to present a special 2 part episode of Allergytalk! Dr. Brian Vickery, the principal investigator of the PALISADE study that led to the first FDA-approved peanut immunotherapy, joins us to discuss his personal story and his thoughts on the future of food immunotherapy! If you have a topic you’d like to cover in a future podcast, let us know at allergytalk@acaai.org
Monday Feb 10, 2020
Episode 7 - Part I: An Interview with Dr. Brian Vickery
Monday Feb 10, 2020
Monday Feb 10, 2020
We are excited to present a special 2 part episode of Allergytalk! Dr. Brian Vickery, the principal investigator of the PALISADE study that led to the first FDA-approved peanut immunotherapy, joins us to discuss his personal story and his thoughts on the future of food immunotherapy! If you have a topic you’d like to cover in a future podcast, let us know at allergytalk@acaai.org.
Tuesday Oct 29, 2019
Episode 6: Telemedicine in allergy/immunology
Tuesday Oct 29, 2019
Tuesday Oct 29, 2019
We are excited to present a special episode of Allergytalk! Dr. Jennifer Shih, MD joins the podcast to discuss the use of telemedicine in allergy/immunology!
Please give us feedback, corrections, and suggestions!
If you have a topic you’d like to cover in a future podcast, let us know at allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Dr. Lee was on an advisory board for Teva.
Dr. Kalangara has received consulting fees from AstraZeneca.
Dr. Shih was on advisory board for Teva and Tekeda.
Wednesday Oct 02, 2019
Wednesday Oct 02, 2019
This is part 2 of our summaries from the July-August 2019 issue of Allergy Watch:
Investigation of the factors that determine the severity of allergic reactions to Hymenoptera venoms
https://www.ncbi.nlm.nih.gov/pubmed/30819281
New-Onset Asthma in Adults: What Does the Trigger History Tell Us?
https://www.ncbi.nlm.nih.gov/pubmed/30240884
Age-Specific Associations of Ozone and Fine Particulate Matter with Respiratory Emergency Department Visits in the United States
https://www.ncbi.nlm.nih.gov/pubmed/30277796
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Dr. Lee was on an advisory board for Teva.
Dr. Kalangara has received consulting fees from AstraZeneca.
Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.
Wednesday Oct 02, 2019
Wednesday Oct 02, 2019
For today’s episode we will be reviewing three articles from the July-August 2019 issue of Allergy Watch:
Dupilumab reduces local type 2 pro-inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis
https://www.ncbi.nlm.nih.gov/pubmed/30488542
Allergen content in German cockroach extracts and sensitization profiles to a new expanded set of cockroach allergens determine in vitro extract potency for IgE reactivity
https://www.ncbi.nlm.nih.gov/pubmed/30170124
New IgE immediate hypersensitivity reactions on reintroduction of food restricted for treatment of eosinophilic esophagitis
https://www.ncbi.nlm.nih.gov/pubmed/30684739
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Dr. Lee was on an advisory board for Teva.
Dr. Kalangara has received consulting fees from AstraZeneca.
Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, Shire; Research: Aimmune, DBV, Shire, Regeneron.
Tuesday Jul 23, 2019
Episode 3: Food Allergy & Eczema
Tuesday Jul 23, 2019
Tuesday Jul 23, 2019
For today’s episode we will be reviewing three articles about food allergy and eczema from the May-June 2019 issue of Allergy Watch:
The Basophil Activation Test reduces the need for a food challenge test in children suspected of IgE-mediated cow's milk allergy.https://www.ncbi.nlm.nih.gov/pubmed/30408255
Oral food challenge failures among foods restricted because of atopic dermatitis.https://www.ncbi.nlm.nih.gov/pubmed/30326323
The nonlesional skin surface distinguishes atopic dermatitis with food allergy as a unique endotype.https://www.ncbi.nlm.nih.gov/pubmed/30787169
Please give us feedback, corrections, and suggestions!
Email feedback to: allergytalk@acaai.org
ACAAI is presenting this podcast for educational purposes only. It is not medical advice or intended to replace the judgment of a licensed physician. The College is not responsible for any claims related to procedures, professionals, products or methods discussed in the podcast, and it does not approve or endorse any products, professionals, services or methods that might be referenced.
Today’s speakers have the following disclosures:
Dr. Lee was on an advisory board for Teva.
Dr. Kalangara has received consulting fees from Astra Zenica.
Dr. Fineman Speaker: AstraZenca, Boehringer Ingelheim, ShireResearch: Aimmune, DBV, Shire, Regeneron.







